522 related articles for article (PubMed ID: 19523858)
1. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
2. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
[TBL] [Abstract][Full Text] [Related]
3. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
[TBL] [Abstract][Full Text] [Related]
4. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
5. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
6. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
7. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
[TBL] [Abstract][Full Text] [Related]
9. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.
Pryma DA; O'Donoghue JA; Humm JL; Jungbluth AA; Old LJ; Larson SM; Divgi CR
J Nucl Med; 2011 Apr; 52(4):535-40. PubMed ID: 21421715
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
[TBL] [Abstract][Full Text] [Related]
13. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Yang X; Minn I; Rowe SP; Banerjee SR; Gorin MA; Brummet M; Lee HS; Koo SM; Sysa-Shah P; Mease RC; Nimmagadda S; Allaf ME; Pomper MG
Oncotarget; 2015 Oct; 6(32):33733-42. PubMed ID: 26418876
[TBL] [Abstract][Full Text] [Related]
14. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Oosterwijk-Wakka JC; Kats-Ugurlu G; Leenders WP; Kiemeney LA; Old LJ; Mulders PF; Oosterwijk E
BJU Int; 2011 Jan; 107(1):118-25. PubMed ID: 20346054
[TBL] [Abstract][Full Text] [Related]
15. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
16. Targeting CAIX with [
Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
[TBL] [Abstract][Full Text] [Related]
18. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.
Garousi J; Honarvar H; Andersson KG; Mitran B; Orlova A; Buijs J; Löfblom J; Frejd FY; Tolmachev V
Mol Pharm; 2016 Nov; 13(11):3676-3687. PubMed ID: 27529191
[TBL] [Abstract][Full Text] [Related]
19. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Chrastina A; Pastoreková S; Pastorek J
Neoplasma; 2003; 50(1):13-21. PubMed ID: 12687273
[TBL] [Abstract][Full Text] [Related]
20. Preclinical validation of
Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]